Company Description
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.
The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products.
The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments.
The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products.
The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system.
The company was founded in 1949 and is headquartered in Galway, Ireland.
| Country | Ireland |
| Founded | 1949 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 95,000 |
| CEO | Geoffrey Martha |
Contact Details
Address: Building Two, Parkmore Business Park West Galway Ireland | |
| Phone | 353 1 438 1700 |
| Website | medtronic.com |
Stock Details
| Ticker Symbol | MDT |
| Exchange | NYSE |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001613103 |
| CUSIP Number | G5960L103 |
| ISIN Number | IE00BTN1Y115 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Geoffrey Straub Martha | Chairman of the Board and Chief Executive Officer |
| Sean M. Salmon | Executive Vice President and President of Cardiovascular Portfolio |
| Brett A. Wall | Executive Vice President and President of Neuroscience Portfolio |
| Gregory L. Smith | Executive Vice President of Global Operations and Supply Chain |
| Gary Corona | Senior Vice President of Global Financial Planning and Analysis and Interim Chief Financial Officer |
| Mark Ploof | Senior Vice President of Global Operations and Business Services |
| Jennifer M. Kirk | Senior Vice President, Global Controller and Chief Accounting Officer |
| Dr. Kenneth E. Washington Ph.D. | Senior Vice President and Chief Technology and Innovation Officer |
| Dr. Laura Mauri M.D., M.Sc. | Senior Vice President and Chief Scientific and Medical Officer |
| Ryan Weispfenning | Vice President and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | 144 | Filing |
| Oct 30, 2024 | 144 | Filing |
| Oct 29, 2024 | 144 | Filing |
| Oct 24, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Oct 24, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Oct 24, 2024 | 144 | Filing |
| Oct 23, 2024 | 144 | Filing |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 144 | Filing |
| Oct 17, 2024 | 144 | Filing |